The Economist podcast examines Ozempic’s neurological impact and Japan’s startup deficit
The latest episode from The Economist explores the potential neurological effects of Ozempic, the structural reasons behind Japan’s lack of high-growth startups, and strategies to overcome procrastination.
The Economist’s daily podcast, titled “Wake-up haul: an Ozempic moment for the brain”, has released a new episode that intersects health, economics, and behavioural science. Published on 19 August 2026, the discussion moves beyond the drug’s established role in diabetes management and weight loss to investigate its potential impact on brain health.
The episode’s title references a potential “Ozempic moment” for the brain, suggesting that emerging discourse may be highlighting significant neurological developments or effects associated with the medication. While the summary does not provide definitive medical conclusions or specific scientific data, the framing indicates a growing focus on how such pharmaceutical interventions might influence cognitive function or neurological outcomes.
Shifting from healthcare to corporate valuation, the podcast also addresses the economic landscape in Japan. A key segment of the discussion is dedicated to understanding why Japan has so few unicorn companies. In financial terms, unicorns are defined as privately held startup companies valued at over $1 billion. The analysis seeks to explain the scarcity of these high-growth entities within Japan compared to other major global economies.
This focus on Japan’s startup ecosystem highlights a broader structural contrast. While nations like the United States have seen a proliferation of high-growth tech startups, Japan’s economic history has been characterised by a lower prevalence of such ventures. The podcast aims to unpack the specific reasons behind this disparity, offering insight into the barriers or conditions that limit the emergence of billion-dollar private firms in the region.
Finally, the episode concludes with a segment on behavioural productivity, specifically offering strategies to stop procrastinating. This addition to the daily digest provides practical advice on overcoming a common challenge, rounding out a diverse range of topics that span from pharmaceutical science to macroeconomic trends and individual psychology.
